Danaher Corporation's second-quarter bioprocessing unit miss sent ripples across the life sciences sector, pressuring Bio-Rad Laboratories shares in early New York trading. Danaher reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS rising 8% to $1.94 and free cash flow of $1.3 billion, and raised its full-year adjusted EPS guidance to $8.45–$8.60. Bio-Rad posted Q2 net sales of $651 million, essentially flat, with its Life Science segment down 4.1% to $252 million, and announced a restructuring plan on July 31, 2026 involving global headcount reductions and facility closures expected to generate $80 million to $90 million in pre-tax charges. RBC Capital subsequently raised its price target on Bio-Rad to $370 from $320, maintaining an Outperform rating, while Danaher named Julie Sawyer Montgomery as CEO. Hedge fund data showed institutional investors trimmed positions in both stocks during Q1 2026, with Bio-Rad held by 35 hedge funds and Danaher by 110.
Danaher CorporationDanaher raised full-year adjusted EPS guidance and named a new CEO, despite bioprocessing miss.
Bio-Rad Laboratories IncDanaher's bioprocessing miss pressures life sciences sector, and Bio-Rad's Life Science segment declined 4.1%.
Royal Bank of Canada
Sartorius Aktiengesellschaft